X4 Pharmaceuticals (XFOR) to Release Quarterly Earnings on Thursday

X4 Pharmaceuticals (NASDAQ:XFOR) is anticipated to announce its Q1 2025 earnings results before the market opens on Thursday, May 1st. Analysts expect X4 Pharmaceuticals to post earnings of ($0.14) per share and revenue of $7.03 million for the quarter.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($6.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($5.10) by ($0.90). The company had revenue of $1.43 million for the quarter, compared to analyst estimates of $1.07 million. On average, analysts expect X4 Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

X4 Pharmaceuticals Price Performance

Shares of NASDAQ:XFOR traded down $0.24 during trading on Tuesday, hitting $5.10. 60,585 shares of the company were exchanged, compared to its average volume of 91,864. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. X4 Pharmaceuticals has a 1-year low of $4.95 and a 1-year high of $37.50. The company has a market capitalization of $885.68 million, a P/E ratio of -57.38 and a beta of 0.58. The business’s 50 day moving average is $8.45 and its 200-day moving average is $13.49.

Wall Street Analyst Weigh In

XFOR has been the topic of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $90.00 price target on shares of X4 Pharmaceuticals in a report on Wednesday, March 26th. HC Wainwright reissued a “buy” rating and issued a $45.00 price target on shares of X4 Pharmaceuticals in a research note on Thursday, March 27th.

Institutional Investors Weigh In On X4 Pharmaceuticals

A hedge fund recently raised its stake in X4 Pharmaceuticals stock. Bank of America Corp DE lifted its stake in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 20.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 133,502 shares of the company’s stock after buying an additional 22,485 shares during the period. Bank of America Corp DE owned about 0.08% of X4 Pharmaceuticals worth $98,000 at the end of the most recent quarter. 72.03% of the stock is currently owned by institutional investors and hedge funds.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.